Barinthus Biotherapeutics

Company snapshot

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Biotherapeutics. With a broad pipeline, built around four

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Barinthus Biotherapeutics. Not investment advice.

• What is Barinthus Biotherapeutics?

  Centus Biotherapeutics Europe is a pharma organization headquartered in GB. Primary therapeutic focus areas include Carcinoma, Non-Small-Cell Lung. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalT

• Is Barinthus Biotherapeutics publicly traded?

  Barinthus Biotherapeutics appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Barinthus Biotherapeutics develop or market?

  We link 1 drug profile(s) where Barinthus Biotherapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/centus-biotherapeutics-europe-limited#company-drugs.

• What are the latest developments for Barinthus Biotherapeutics?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Barinthus Biotherapeutics focus on?

  Barinthus Biotherapeutics focuses on Carcinoma, Non-Small-Cell Lung based on our analysis of their pipeline programs and drug development activities.